Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TFPM +1.4% (guidance), AZZ +1% (guidance)
Other news:
- DCO +15.3% (confirms receipt of unsolicited, non-binding indication of interest from Albion River)
- BDTX +8.7% (Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535)
- IREN +7.5% (business update) SSL +6.7% (The MInister of Forestry, Fisheries and the Environment upholds Sasol South Africa's Appeal and Permits that a load-based limit be applied to regulate sulphur dioxide emissions from the boilers of the Secunda operations)
- PPTA +6.3% (receives indication for up to $1.8 billion financing from export-import Bank of the United States for Stibnite Gold Project)
- ESPR +5.9% (Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity)
- REAX +5.9% (enters into a settlement agreement to resolve the pending class action litigation; has committed to paying $9.25 mln into a qualified settlement fund)
- SNDX +4.6% (Presents Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session)
- OCUL +4% (Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting )
- CDE +3.7% (files prospectus supplement relating to resale of up to 737,210 shares by the selling stockholders)
- INZY +3% (announces positive topline data from ongoing phase 1/2 trials of inz-701 in adults with ABCC6 deficiency and ENPP1 deficiency)
- IONS +2.6% (presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome)
- TSLA +2.5% (Elon Musk tweets that Tesla Robotaxi will be unveiled on 8/8)
- LEGN +2.5% (Johnson & Johnson and Legend Biotech (LEGN) receive FDA approval for CARVYKTI)
- BEPC +2.4% (files for $2.5 bln offering of class A exchangeable subordinate voting shares)
- OGN +2.2% (Phase 3 comparative clinical study of Prolia and Xgeva biosimilar candidate HLX14 met primary endpoints)
- ARWR +2% (Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo)
- TSM +1.7% (Arizona and U.S. Department of Commerce announce up to $6.6 billion in proposed chips act direct funding, the company plans third leading-edge fab in phoenix)
- AMRN +1% (reports new REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups)
Analyst comments:
- FSLY +4.4% (upgraded to Overweight from Neutral at Piper Sandler)
- BJ +2.5% (upgraded to Buy from Neutral at Goldman)
- GEV +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- HBAN +1.8% (upgraded to Buy from Neutral at BofA Securities; upgraded to Buy from Hold at Jefferies)
- AMAT +1.7% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- BRP +1.5% (upgraded to Overweight from Neutral at JP Morgan)